Feeds:
Posts
Comments

Posts Tagged ‘Amylin’

*****

TODAY’S NEWS

New experimental RA/Lupus drug suspended after patient deaths – Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s futuremore

So, what about Amylin‘s Byetta? The pundits are dueling as potential once-a-week version approval draws near…

An interesting background story on Pfizer‘s expensive oncology “miracle” drug Sutent.

RECOMMENDED

Training new (or experienced) brand managers? – We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

A “trifecta” social media approach – Novartis sponsors a community, Twitter account, and Facebook Fan Page for Cystic Fibrosis patients. How are they doing? An Impactiviti review.

JUST FOR FUN

Top 10 Most Stupid Inventions. No disagreement here!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

TODAY’S NEWS

Big change – Dan Vasella to step aside as Novartis CEO. This article also details the other internal leadership changes – very interesting.

Novo Nordisk gets approval for new diabetes drug Victoza – Federal health officials on Monday approved Danish drugmaker Novo Nordisk’s once-daily injection for treating type 2 diabetes but said more safety studies are needed before it can be cleared as a first-line treatment for the disease. The Food and Drug Administration said it approved the drug, Victoza, to help lower blood sugar levels when coupled with diet, exercise and other diabetes medicines. It was not recommended as an initial therapy for patients who have not been able to control their diabetes with diet and exercise alonemore Meanwhile, Amylin waiting for once-weekly treatment to be approved.

Will 2010 be a big year for big pharma?

No matter what, I’ll still enjoy red wine – GlaxoSmithKline shocked the pharmaceutical industry in 2008 when it dropped $720 million to buy Sirtris Pharmaceuticals, a biotechnology company working on drugs based on resveratrol, a chemical in red wine thought to combat the effects of aging. But now researchers at rival companies are openly questioning whether the compounds will work. They say they are unable to replicate key laboratory experiments backing the drugs’ promisemore

RECOMMENDED

Selling to the C-Suite – Do your sales executives need to be better prepared to sell all the way up to the C-Suite? We can help with that. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The post I keep wanting to write…but haven’t yet. Well, I finally partially wrote it….

JUST FOR FUN

Dilbert on Doing What Matters. :>}

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

FDA warning letters to Lilly, Bayer, Amylin, Cephalon.

Wow: ARBs for hypertension reducing Alzheimer’s symptoms? – Drugs commonly used to lower blood pressure, sold by AstraZeneca Plc, Sanofi-Aventis SA and Merck & Co., may also reduce the risk of developing Alzheimer’s disease. Researchers from Boston University analyzed the medical records of more than 800,000 U.S. veterans and found those taking angiotensin receptor blockers were up to 24 percent less likely to develop dementia than patients on other medications. Patients already diagnosed with Alzheimer’s disease were half as likely to be admitted to a nursing home and had a 17 percent reduced risk of dying if they were taking the medicationsmore

FTC wants to put a stop to the “pay-to-delay” deals – Jon Leibowitz will hold a press conference today to ask Congress to include a provision in the health care reform bill to end deals in which brand-name drugmakers offer payments or other inducments to generic rivals to delay copycat versions of best-selling medsmore

RECOMMENDED

Product/Therapeutic training development (pharma/biotech/devices). Live training, modules, eLearning – we’ve got the expertise and customer-centric approach in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media, Opportunity, and Serendipity – my guest post on the Hive Awards blog.

JUST FOR FUN

Visual awesomeness. Photo of Martian dune field. Quite spectacular!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!

TODAY’S NEWS

Amylin to be led by former Novartis exec – Amylin Pharmaceuticals has taken another step forward in its long & storied history. The company has announced that former Novartis executive Paulo Costa will become its new chairmanmore

An interesting lawsuit: individual suing Celgene for blockbuster drug idea – In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myelomamore

Gene variation impacts 1/3 of Plavix patients? – A common gene variation explains why many people are not helped by the widely prescribed blood thinner Plavix, U.S. researchers said on Tuesday in a study confirming earlier research and paving the way for tests to screen patients before they get the drugmore

From the rumor mill – Glaxo eyeing Human Genome Sciences? And, is B-I cutting a major percentage of its sales force in the U.S.? (can anyone confirm or deny with facts?)

RECOMMENDED

Corporate HR workshops – Sexual Harassment. Compliance. Communications. Ethics. Diversity. The Impactiviti Partner Network has what you need. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Are placebos getting more effective? What’s going on here? – From 2001 to 2006, the percentage of new products cut from development after Phase II clinical trials, when drugs are first tested against placebo, rose by 20 percent. The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebomore

JUST FOR FUN

Who’s got the better colors? An eye-popping series of 3 photos you’ll enjoy!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Abbott and J&J to duke it out in court over a patent dispute on new rheumatoid arthritis drug.

Amylin eliminating 200 sales positionsDrugmaker Amylin Pharmaceuticals Inc. said Monday it will eliminate about 200 jobs, or more than a third of its sales force, as it combines its primary care and specialty drug sales units.Amylin partners with Eli Lilly & Co. to sell the diabetes drug Byetta, and is also developing a once-per-week version through that alliance. Amylin said the reorganization of its sales force will strengthen the partnership.

Gelnique works for OAB Applying a gel containing the anti-spasmodic agent oxybutynin to the skin is safe and effective for women with overactive bladder, according to a study reported here at the annual meeting of the American Urological Association.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Avastin + Tarceva = better results in lung cancerGenentech said the trial was stopped early after an interim analysis found that combining Avastin, known generically as bevacizumab, and Tarceva, or erlotinib, significantly extended the time patients with non-small cell lung cancer lived without their disease advancing.

Amylin‘s leadership under fire from Carl Icahn and others – “While we have not lost faith in the potential of Amylin’s products and pipeline, we have lost confidence in Amylin’s leadership to take this rich product portfolio and execute an operational strategy that is in the best interest of the shareholders…”

Does insulin help protect brains from the development of Alzheimer’s? – Insulin appears to shield the brain from toxic proteins associated with Alzheimer’s disease, U.S. researchers said on Monday, supporting a theory that Alzheimer’s may be a third form of diabetes.

PLUS – the usual rumor mill: blah, blah, blah…Sanofi-Aventis…blah, blah, blah…Bristol Myers-Squibb. You know the drill. And, business advice from the NY Times for navigating through a downturn.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Reblog this post [with Zemanta]

Read Full Post »

Astellas makes a big to acquire CV Therapeutics. Japan’s Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday’s close.

Abilify as an add-on therapy for depression – not everyone is convinced.

Watson‘s topical Overactive Bladder gel (Gelnique) gets FDA approval.

PLUS – Amylin hurting. Abbott‘s Vicodin CR delay means 200 layoffs. And Feds say, “Enough with the off-label promotion already!

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.

Reblog this post [with Zemanta]

Read Full Post »

Older Posts »